Agenus Inc. (AGEN)Healthcare | Biotechnology | Lexington, United States | NasdaqCM
6.68 USD
+0.18
(2.769%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 4:21 a.m. EDT
The long-term outlook is severely compromised by a brutal multi-year decline; the stock has lost over 97% of its value over the last nine years, with four consecutive years of negative returns ending recently. Despite a recent surge in share price and positive news regarding financing, the underlying business shows no signs of a sustainable turnaround, evidenced by negative free cash flow and a forward P/E that implies continued losses. The short-term rating is neutral because the recent price rally appears to be a volatile reaction to financing news rather than a confirmed trend reversal, especially given the overwhelming defensive positioning in the options market. With no dividend to provide income and a balance sheet showing net debt, this remains a high-risk speculative vehicle rather than an investment. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.076793 |
| AutoARIMA | 0.077156 |
| MSTL | 0.082566 |
| AutoTheta | 0.331887 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 4.46 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.219 |
| Excess Kurtosis | 0.12 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 3.645 |
| Market Cap | 301,681,600 |
| Trailing P/E | 2.64 |
| Forward P/E | -60.73 |
| Beta | 1.32 |
| Profit Margins | 69.34% |
| Website | https://www.agenusbio.com |
As of Oct. 10, 2026, 4:21 a.m. EDT: Speculators are positioning defensively with heavy put volume at strikes significantly below the current price (e.g., $3.00 and $4.00 expiring Nov '26), suggesting a fear of a deep decline. Conversely, there is notable call interest at distant strikes ($15.00 expiring Jan '29), indicating a speculative bet on a massive recovery or biotech catalyst, while near-term call activity remains thin relative to the put volume.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.6741855 |
| Address1 | 3 Forbes Road |
| All Time High | 7,065.751 |
| All Time Low | 1.38 |
| Ask | 8.78 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,000,350 |
| Average Daily Volume3 Month | 1,327,298 |
| Average Volume | 1,327,298 |
| Average Volume10Days | 1,000,350 |
| Beta | 1.324 |
| Bid | 5.25 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | -4.671 |
| City | Lexington |
| Compensation As Of Epoch Date | 1,672,444,800 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.68 |
| Current Ratio | 0.34 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 6.99 |
| Day Low | 6.51 |
| Display Name | Agenus |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,747,053,000 |
| Earnings Call Timestamp Start | 1,747,053,000 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | 40,610,000 |
| Ebitda Margins | 0.30604 |
| Enterprise To Ebitda | 7.78 |
| Enterprise To Revenue | 2.381 |
| Enterprise Value | 315,931,328 |
| Eps Current Year | 0.5 |
| Eps Forward | -0.11 |
| Eps Trailing Twelve Months | 2.53 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 781 674 4200 |
| Fifty Day Average | 7.752 |
| Fifty Day Average Change | -1.072 |
| Fifty Day Average Change Percent | -0.1382869 |
| Fifty Two Week Change Percent | 67.41855 |
| Fifty Two Week High | 10.31 |
| Fifty Two Week High Change | -3.6300006 |
| Fifty Two Week High Change Percent | -0.3520854 |
| Fifty Two Week Low | 2.71 |
| Fifty Two Week Low Change | 3.9699998 |
| Fifty Two Week Low Change Percent | 1.4649446 |
| Fifty Two Week Range | 2.71 - 10.31 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 950,020,200,000 |
| Float Shares | 40,227,084 |
| Forward Eps | -0.11 |
| Forward P E | -60.727272 |
| Free Cashflow | -74,785,872 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 81 |
| Fullday Change | -0.029999733 |
| Fullday Change Percent | -0.4490978 |
| Fullday Price | 6.65 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 1.13608 |
| Gross Profits | 150,750,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06268 |
| Held Percent Institutions | 0.46427 |
| Implied Shares Outstanding | 45,161,916 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.agenusbio.com/investors/performance.shtml |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,712,880,000 |
| Last Split Factor | 1:20 |
| Long Business Summary | Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. |
| Long Name | Agenus Inc. |
| Market | us_market |
| Market Cap | 301,681,600 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_409956 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 91,795,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 379,360,094 |
| Number Of Analyst Opinions | 3 |
| Open | 6.51 |
| Operating Cashflow | -98,504,000 |
| Operating Margins | 0.32716 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.44 |
| Phone | 781 674 4400 |
| Pre Market Change | -0.029999733 |
| Pre Market Change Percent | -0.4490978 |
| Pre Market Price | 6.65 |
| Pre Market Time | 1,792,144,931 |
| Previous Close | 6.5 |
| Price Eps Current Year | 13.36 |
| Price Hint | 2 |
| Price To Book | -1.4301006 |
| Price To Sales Trailing12 Months | 2.2735307 |
| Profit Margins | 0.69342005 |
| Quick Ratio | 0.319 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.18 |
| Regular Market Change Percent | 2.76923 |
| Regular Market Day High | 6.99 |
| Regular Market Day Low | 6.51 |
| Regular Market Day Range | 6.51 - 6.99 |
| Regular Market Open | 6.51 |
| Regular Market Previous Close | 6.5 |
| Regular Market Price | 6.68 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 814,996 |
| Return On Assets | 0.12532 |
| Revenue Growth | 0.344 |
| Revenue Per Share | 3.645 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 45,161,916 |
| Shares Percent Shares Out | 0.15100001 |
| Shares Short | 6,818,562 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 6,689,181 |
| Short Name | Agenus Inc. |
| Short Percent Of Float | 0.1528 |
| Short Ratio | 6.51 |
| Source Interval | 15 |
| State | MA |
| Symbol | AGEN |
| Target High Price | 40.0 |
| Target Low Price | 14.0 |
| Target Mean Price | 26.33333 |
| Target Median Price | 25.0 |
| Total Cash | 18,738,000 |
| Total Cash Per Share | 0.416 |
| Total Debt | 40,708,000 |
| Total Revenue | 132,693,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.53 |
| Trailing P E | 2.6403162 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.77615 |
| Two Hundred Day Average Change | 1.9038496 |
| Two Hundred Day Average Change Percent | 0.39861593 |
| Type Disp | Equity |
| Volume | 814,996 |
| Website | https://www.agenusbio.com |
| Zip | 02,421-7305 |